Acumen Pharmaceuticals, Inc. filed a Form 8-K on October 30, 2026, disclosing that its Phase 2 ALTITUDE-AD clinical trial of sabirnetug (ACU193) failed to meet its primary endpoint and that the company plans to cease development of the drug.

Key Highlights

  • Primary endpoint missed: The ALTITUDE-AD trial did not meet its primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer's Disease Rating Scale at 18 months versus placebo at either the 35 mg/kg or 50 mg/kg dose, according to the filing.
  • Secondary endpoints also missed: The trial failed to achieve statistical significance on key secondary efficacy endpoints, including the Clinical Dementia Rating - Sum of Boxes, and showed no meaningful difference between either sabirnetug treatment arm and the placebo arm.
  • ARIA-E observed in approximately 10% of treated participants: The initial topline data indicate sabirnetug was generally well tolerated, with amyloid-related imaging abnormalities - edema observed in approximately 10% of sabirnetug-treated participants.
  • Amyloid plaque reduction confirmed: Analysis of amyloid plaque load measured by PET SUVr demonstrated statistically significant amyloid plaque reduction for both dose levels at week 36 and week 76.
  • Development to cease: Based on the topline results, the company disclosed it plans to cease development of sabirnetug, including the open-label extension portion of ALTITUDE-AD.
  • Strategic review initiated: The company disclosed plans to evaluate strategic options, including its Enhanced Brain Delivery (EBD) program, and to implement cash conservation measures.

ALTITUDE-AD Trial Results and Acumen Pharmaceuticals' Next Steps

Acumen Pharmaceuticals (NASDAQ:ABOS) disclosed in its October 30, 2026 Form 8-K that initial topline data from its Phase 2 ALTITUDE-AD clinical trial showed that sabirnetug (ACU193), an investigational treatment for early Alzheimer's disease, did not meet its primary endpoint. According to the filing, the primary endpoint measured change from baseline in cognitive and functional decline using the Integrated Alzheimer's Disease Rating Scale at 18 months compared to placebo, tested at both the 35 mg/kg and 50 mg/kg dose levels.

The filing further disclosed that the trial also failed to achieve statistical significance on key secondary efficacy endpoints, including the Clinical Dementia Rating - Sum of Boxes, and that neither sabirnetug treatment arm showed any meaningful difference compared to the placebo arm. On the safety side, the company reported that sabirnetug was "generally well tolerated," with amyloid-related imaging abnormalities - edema (ARIA-E) observed in approximately 10% of sabirnetug-treated participants. Despite the efficacy failure, the filing noted that a PET SUVr analysis demonstrated statistically significant amyloid plaque reduction for both dose levels at week 36 and week 76.

In response to these results, the company disclosed it plans to cease development of sabirnetug, including the open-label extension portion of ALTITUDE-AD, and to evaluate strategic options, including its Enhanced Brain Delivery (EBD) program. The filing stated the company also plans "to take steps to implement cash conservation measures and explore strategic options to maximize shareholder value." The filing was signed by Matthew Zuga, Chief Financial Officer and Chief Business Officer. The filing notes that the forward-looking statements it contains are subject to risks and uncertainties, including the risk that additional data or further analyses from ALTITUDE-AD may differ from or change the interpretation of the topline results.

What Was Disclosed

Acumen Pharmaceuticals filed an 8-K on October 30, 2026, reporting that its ALTITUDE-AD Phase 2 trial of sabirnetug failed its primary and key secondary endpoints. The company disclosed plans to halt sabirnetug development and evaluate strategic options, including cash conservation measures.